This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Health indices were flat as few stocks peppered an overall dull hump day with a range of announcements.

Geron (GERN) said Wednesday that it would receive a $4 million milestone payment as Merck (MRK) filed an investigational new-drug application for a cancer vaccine candidate. Under a 2005 license agreement between the companies, Geron is eligible for development milestones and royalties on worldwide product sales of vaccines targeting the enzyme telomerase.

Geron shares nudged up 19 cents, or 2.9%, to $6.75. Merck was down 0.5% at $60.08.

Meanwhile another winner emerged after JMP analyst Charles Duncan upgraded Acadia Pharmaceuticals (ACAD) to strong buy from market outperform. The analyst was recently impressed with midstage data on its schizophrenia drug candidate pimavanserin. The company's shares jumped $1.28, or 11.4%, to $12.48. The stock is a component of the Nasdaq biotechnology index, which was hovering just north of the flat line at 852.10.

On the regulatory side, Lannett (LCI) received Food and Drug Administration-approval for the additional indication of the 30-mg dose of its phentermine hydrochloride capsules, the generic equivalent of Teva's (TEVA) Adipex, for short-term management of obesity. The company expects to begin marketing the product immediately. Lannett shares added 20 cents, or 6%, to $3.55.

Elsewhere, Neurocrine (NBIX) is awaiting the FDA's decision on sleep aid indiplon, which is designed to be used as needed to help a person fall back asleep once he or she wakes up in the middle of the night. The FDA rejected the extended-release form last year but granted conditional approval to the immediate-release formula if the company analyzed old data and conducted a test on how the drug was absorbed and excreted by the body and how it reacts with certain foods. Ahead of the FDA's decision, shares were down 18 cents, or 1.7%, to $10.20.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs